ITRM vs. SNSE, ADXN, TCRT, DRRX, FBRX, ALRN, UBX, BFRG, EYEN, and QLI
Should you be buying Iterum Therapeutics stock or one of its competitors? The main competitors of Iterum Therapeutics include Sensei Biotherapeutics (SNSE), Addex Therapeutics (ADXN), Alaunos Therapeutics (TCRT), DURECT (DRRX), Forte Biosciences (FBRX), Aileron Therapeutics (ALRN), Unity Biotechnology (UBX), Bullfrog AI (BFRG), Eyenovia (EYEN), and Qilian International Holding Group (QLI). These companies are all part of the "pharmaceutical preparations" industry.
Iterum Therapeutics (NASDAQ:ITRM) and Sensei Biotherapeutics (NASDAQ:SNSE) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, community ranking, dividends, institutional ownership, analyst recommendations, earnings and valuation.
9.2% of Iterum Therapeutics shares are owned by institutional investors. Comparatively, 10.5% of Sensei Biotherapeutics shares are owned by institutional investors. 5.4% of Iterum Therapeutics shares are owned by company insiders. Comparatively, 25.5% of Sensei Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
In the previous week, Sensei Biotherapeutics had 1 more articles in the media than Iterum Therapeutics. MarketBeat recorded 1 mentions for Sensei Biotherapeutics and 0 mentions for Iterum Therapeutics. Iterum Therapeutics' average media sentiment score of 0.00 equaled Sensei Biotherapeutics'average media sentiment score.
Sensei Biotherapeutics is trading at a lower price-to-earnings ratio than Iterum Therapeutics, indicating that it is currently the more affordable of the two stocks.
Iterum Therapeutics currently has a consensus price target of $6.00, indicating a potential upside of 319.08%. Sensei Biotherapeutics has a consensus price target of $4.00, indicating a potential upside of 310.34%. Given Iterum Therapeutics' higher possible upside, equities research analysts clearly believe Iterum Therapeutics is more favorable than Sensei Biotherapeutics.
Iterum Therapeutics has a beta of 2.36, suggesting that its stock price is 136% more volatile than the S&P 500. Comparatively, Sensei Biotherapeutics has a beta of 0.17, suggesting that its stock price is 83% less volatile than the S&P 500.
Sensei Biotherapeutics' return on equity of -44.01% beat Iterum Therapeutics' return on equity.
Iterum Therapeutics received 113 more outperform votes than Sensei Biotherapeutics when rated by MarketBeat users. However, 75.86% of users gave Sensei Biotherapeutics an outperform vote while only 61.93% of users gave Iterum Therapeutics an outperform vote.
Summary
Sensei Biotherapeutics beats Iterum Therapeutics on 8 of the 12 factors compared between the two stocks.
Get Iterum Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ITRM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ITRM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Iterum Therapeutics Competitors List
Related Companies and Tools
